GUIDANCE DOCUMENT
Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices June 2014
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2014-D-0758
- Issued by:
-
Guidance Issuing OfficeCenter for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research
This draft guidance describes the Food and Drug Administration's (FDA's or Agency) current thinking on recommended practices for drug manufacturers (firms) and their representatives to follow if they choose tp distribute to health care professional2 or health care entities3 scientific or medical journal articles that discuss new risk information for approval prescription drugs4, 5, 6 marketed in the United States.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-D-0758.